(VIANEWS) – EnLink Midstream, LLC (ENLC), ACADIA Pharmaceuticals (ACAD), First Industrial Realty Trust (FR) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. EnLink Midstream, LLC (ENLC)
14.2% sales growth and 10.81% return on equity
EnLink Midstream, LLC provides midstream energy services in the United States. It operates through Permian, Louisiana, Oklahoma, North Texas, and Corporate segments. The company is involved in gathering, compressing, treating, processing, transporting, storing, and selling natural gas; fractionating, transporting, storing, and selling natural gas liquids; and stabilizing, trans-loading , and condensate crude oil , as well as providing brine disposal services. Its midstream energy asset network includes approximately 12,100 miles of pipelines; 22 natural gas processing plants;7 fractionators with approximately 320,000 barrels per day; barge and rail terminals; product storage facilities; brine disposal wells; and a crude oil trucking fleet. The company was incorporated in 2013 and is based in Dallas, Texas.
Earnings Per Share
As for profitability, EnLink Midstream, LLC has a trailing twelve months EPS of $0.3.
PE Ratio
EnLink Midstream, LLC has a trailing twelve months price to earnings ratio of 44.27. Meaning, the purchaser of the share is investing $44.27 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 10.81%.
Sales Growth
EnLink Midstream, LLC’s sales growth is 0.4% for the present quarter and 14.2% for the next.
Volume
Today’s last reported volume for EnLink Midstream, LLC is 754856 which is 65.41% below its average volume of 2182390.
2. ACADIA Pharmaceuticals (ACAD)
10.6% sales growth and 6.7% return on equity
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. The company also develops Trofinetide, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome; Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-204 for the treatment of Alzheimer's disease psychosis; antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. The company was founded in 1993 and is headquartered in San Diego, California.
Earnings Per Share
As for profitability, ACADIA Pharmaceuticals has a trailing twelve months EPS of $0.19.
PE Ratio
ACADIA Pharmaceuticals has a trailing twelve months price to earnings ratio of 83.84. Meaning, the purchaser of the share is investing $83.84 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 6.7%.
Sales Growth
ACADIA Pharmaceuticals’s sales growth is 17.5% for the present quarter and 10.6% for the next.
Moving Average
ACADIA Pharmaceuticals’s value is below its 50-day moving average of $16.77 and way below its 200-day moving average of $20.45.
Growth Estimates Quarters
The company’s growth estimates for the present quarter is 135% and a drop 67.9% for the next.
3. First Industrial Realty Trust (FR)
9.8% sales growth and 11.15% return on equity
First Industrial Realty Trust, Inc. (NYSE: FR) is a leading fully integrated owner, operator, and developer of industrial real estate with a track record of providing industry-leading customer service to multinational corporations and regional customers. Across major markets in the United States, our local market experts manage, lease, buy, (re)develop, and sell bulk and regional distribution centers, light industrial, and other industrial facility types. In total, we own and have under development approximately 64.1 million square feet of industrial space as of September 30, 2020.
Earnings Per Share
As for profitability, First Industrial Realty Trust has a trailing twelve months EPS of $2.13.
PE Ratio
First Industrial Realty Trust has a trailing twelve months price to earnings ratio of 26.48. Meaning, the purchaser of the share is investing $26.48 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 11.15%.
4. Expedia Group (EXPE)
5.9% sales growth and 25.46% return on equity
Expedia Group, Inc. operates as an online travel company in the United States and internationally. The company operates through B2C, B2B, and trivago segments. Its B2C segment includes Brand Expedia, a full-service online travel brand offers various travel products and services; Hotels.com for lodging accommodations; Vrbo, an online marketplace for the alternative accommodations; Orbitz, Travelocity, Wotif Group, ebookers, CheapTickets, Hotwire.com and CarRentals.com. The company's B2B segment provides various travel and non-travel companies including airlines, offline travel agents, online retailers, corporate travel management, and financial institutions who leverage its travel technology and tap into its diverse supply to augment their offerings and market Expedia Group rates and availabilities to its travelers. Its trivago segment, a hotel metasearch website, which send referrals to online travel companies and travel service providers from hotel metasearch websites. In addition, the company provides brand advertising through online and offline channels, loyalty programs, mobile apps, and search engine marketing, as well as metasearch, social media, direct and personalized traveler communications on its websites, and through direct e-mail communication with its travelers. The company was formerly known as Expedia, Inc. and changed its name to Expedia Group, Inc. in March 2018. Expedia Group, Inc. was founded in 1996 and is headquartered in Seattle, Washington.
Earnings Per Share
As for profitability, Expedia Group has a trailing twelve months EPS of $5.32.
PE Ratio
Expedia Group has a trailing twelve months price to earnings ratio of 24.52. Meaning, the purchaser of the share is investing $24.52 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 25.46%.
Previous days news about Expedia Group(EXPE)
- According to Zacks on Tuesday, 3 September, "Stiff competition from the likes of TripAdvisor (TRIP Quick QuoteTRIP – Free Report) , Airbnb (ABNB Quick QuoteABNB – Free Report) and Expedia Group (EXPE Quick QuoteEXPE – Free Report) , which are also making continuous efforts toward bolstering travel initiatives, pose a risk to BKNG’s market position."
